Close Menu

NEW YORK (GenomeWeb) – OpGen announced today it has partnered with the New York State Department of Health and Ilúm Health Solutions, a subsidiary of Merck's Healthcare Services and Solutions, to build an antimicrobial resistance tracking tool for the state healthcare system.

OpGen will receive a $1.5 million contract for a 12-month demonstration portion of the project, according to a statement, with potential for full implementation during the next five years, depending on meeting certain milestones. Further terms of the partnership were not disclosed

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

A new blood test might be able to detect the presence of some 50 cancers, according to New Scientist.

Undark looks into how coronavirus-related shutdowns are affecting field researchers.

In PNAS this week: strategies to design DNA oligonucleotide probes for bacteria, Vibrio cholerae evolution in Haiti, and more.

Politico reports President Donald Trump has signed the $2 trillion coronavirus relief package.

May
06
Sponsored by
Isoplexis

This webinar will discuss the application of single-cell proteomics and immune-imaging in adoptive cell therapy (ACT) for cancer.